Xencor (XNCR) Stock Forecast, Price Target & Predictions
XNCR Stock Forecast
Xencor stock forecast is as follows: an average price target of $42.60 (represents a 97.96% upside from XNCR’s last price of $21.52) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
XNCR Price Target
XNCR Analyst Ratings
Xencor Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jun 14, 2024 | Etzer Darout | BMO Capital | $32.00 | $20.89 | 53.15% | 48.70% |
Jun 14, 2024 | Gregory Renza | RBC Capital | $31.00 | $20.99 | 47.69% | 44.05% |
Apr 16, 2024 | Kaveri Pohlman | BTIG | $38.00 | $20.11 | 88.96% | 76.58% |
Oct 04, 2021 | Charles Zhu | Guggenheim | $54.00 | $35.52 | 52.03% | 150.93% |
May 05, 2021 | Dane Leone | Raymond James | $58.00 | $40.76 | 42.30% | 169.52% |
Xencor Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 3 |
Avg Price Target | - | - | $33.67 |
Last Closing Price | $21.52 | $21.52 | $21.52 |
Upside/Downside | -100.00% | -100.00% | 56.46% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 26, 2024 | RBC Capital | Outperform | Outperform | Hold |
Jun 14, 2024 | BMO Capital | Outperform | Outperform | Hold |
Jun 14, 2024 | RBC Capital | Outperform | Outperform | Hold |
May 10, 2024 | Wedbush | Buy | Buy | Hold |
Apr 16, 2024 | Wedbush | Buy | Buy | Hold |
Apr 16, 2024 | BTIG | Buy | Buy | Hold |
Feb 28, 2024 | Wedbush | Buy | Buy | Hold |
Feb 28, 2024 | RBC Capital | Underperform | Underperform | Hold |
Dec 06, 2022 | Cowen & Co. | - | Outperform | Initialise |
Oct 13, 2022 | Raymond James | - | Strong Buy | Upgrade |
Xencor Financial Forecast
Xencor Revenue Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $44.69M | $59.16M | $45.52M | $18.96M | $21.61M | $27.30M | $30.18M | $85.50M | $154.01M | $19.68M | $67.45M | $33.97M | $41.85M | $35.37M | $13.09M | $32.38M | $3.52M | $21.76M |
Avg Forecast | $20.57M | $20.57M | $20.57M | $20.57M | $18.93M | $17.55M | $15.97M | $14.67M | $24.45M | $14.59M | $20.00M | $23.07M | $77.63M | $30.01M | $26.25M | $28.72M | $20.07M | $21.05M | $34.01M | $26.14M | $76.29M | $20.74M | $18.51M | $16.01M | $30.51M | $36.01M | $11.71M | $14.64M | $14.31M | $6.72M |
High Forecast | $20.57M | $20.57M | $20.57M | $20.57M | $18.93M | $17.55M | $15.97M | $14.67M | $24.45M | $32.05M | $20.56M | $23.07M | $121.33M | $30.01M | $26.25M | $28.72M | $20.07M | $21.05M | $34.01M | $26.14M | $76.29M | $20.74M | $18.51M | $16.01M | $30.51M | $36.01M | $11.71M | $14.64M | $14.31M | $6.72M |
Low Forecast | $20.57M | $20.57M | $20.57M | $20.57M | $18.93M | $17.55M | $15.97M | $14.67M | $24.45M | $1.38M | $19.44M | $23.07M | $11.03M | $30.01M | $26.25M | $28.72M | $20.07M | $21.05M | $34.01M | $26.14M | $76.29M | $20.74M | $18.51M | $16.01M | $30.51M | $36.01M | $11.71M | $14.64M | $14.31M | $6.72M |
# Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 7 | 6 | 5 | 5 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.58% | 1.97% | 1.73% | 0.66% | 1.08% | 1.30% | 0.89% | 3.27% | 2.02% | 0.95% | 3.64% | 2.12% | 1.37% | 0.98% | 1.12% | 2.21% | 0.25% | 3.24% |
Xencor EBITDA Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 7 | 6 | 5 | 5 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-33.47M | $-18.27M | $-26.00M | $-59.37M | $-42.59M | $-41.41M | $-19.23M | $32.07M | $75.17M | $-38.20M | $54.00M | $-849.00K | $1.52M | $-11.10M | $-33.58M | $-6.70M | $-25.98M | $-9.50M |
Avg Forecast | $-6.73M | $-6.73M | $-6.73M | $-6.73M | $-6.19M | $-5.74M | $-5.22M | $-4.80M | $-7.99M | $-4.77M | $-6.54M | $-7.54M | $-25.39M | $-9.81M | $-8.59M | $-9.39M | $-6.56M | $-6.88M | $-11.12M | $-8.55M | $-24.95M | $-6.78M | $-6.05M | $-1.48M | $-9.98M | $-11.77M | $-3.83M | $-9.84M | $-4.68M | $-2.20M |
High Forecast | $-6.73M | $-6.73M | $-6.73M | $-6.73M | $-6.19M | $-5.74M | $-5.22M | $-4.80M | $-7.99M | $-450.06K | $-6.36M | $-7.54M | $-3.61M | $-9.81M | $-8.59M | $-9.39M | $-6.56M | $-6.88M | $-11.12M | $-8.55M | $-24.95M | $-6.78M | $-6.05M | $-1.19M | $-9.98M | $-11.77M | $-3.83M | $-7.87M | $-4.68M | $-2.20M |
Low Forecast | $-6.73M | $-6.73M | $-6.73M | $-6.73M | $-6.19M | $-5.74M | $-5.22M | $-4.80M | $-7.99M | $-10.48M | $-6.72M | $-7.55M | $-39.67M | $-9.81M | $-8.59M | $-9.39M | $-6.56M | $-6.88M | $-11.12M | $-8.55M | $-24.95M | $-6.78M | $-6.05M | $-1.78M | $-9.98M | $-11.77M | $-3.83M | $-11.81M | $-4.68M | $-2.20M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.32% | 1.86% | 3.03% | 6.32% | 6.49% | 6.02% | 1.73% | -3.75% | -3.01% | 5.63% | -8.92% | 0.57% | -0.15% | 0.94% | 8.77% | 0.68% | 5.55% | 4.32% |
Xencor Net Income Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 7 | 6 | 5 | 5 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-19.10M | $-24.27M | $-21.95M | $-59.92M | $-12.04M | $-32.76M | $-39.95M | $23.59M | $73.06M | $-40.19M | $52.25M | $-2.49M | $-13.69K | $-12.55M | $-35.02M | $-8.07M | $-26.91M | $-10.22M |
Avg Forecast | $-54.89M | $-54.89M | $-55.51M | $-55.51M | $-61.55M | $-59.24M | $-59.86M | $-58.90M | $-48.73M | $-60.54M | $-51.24M | $90.05M | $-6.54M | $-44.80M | $-49.16M | $71.18M | $866.88M | $-41.70M | $-30.46M | $56.27M | $1.73M | $-38.92M | $-36.19M | $-4.34M | $-23.36M | $-13.79M | $-31.64M | $-11.86M | $-25.35M | $-33.64M |
High Forecast | $-54.89M | $-54.89M | $-55.51M | $-55.51M | $-61.55M | $-59.24M | $-59.86M | $-58.90M | $-48.73M | $-52.51M | $-51.24M | $108.06M | $24.52M | $-44.80M | $-49.16M | $85.42M | $1.04B | $-41.70M | $-30.46M | $67.53M | $1.73M | $-38.92M | $-36.19M | $-3.47M | $-23.36M | $-13.79M | $-31.64M | $-9.48M | $-25.35M | $-33.64M |
Low Forecast | $-54.89M | $-54.89M | $-55.51M | $-55.51M | $-61.55M | $-59.24M | $-59.86M | $-58.90M | $-48.73M | $-66.72M | $-51.24M | $72.04M | $-34.33M | $-44.80M | $-49.16M | $56.95M | $693.50M | $-41.70M | $-30.46M | $45.02M | $1.73M | $-38.92M | $-36.19M | $-5.21M | $-23.36M | $-13.79M | $-31.64M | $-14.23M | $-25.35M | $-33.64M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.92% | 0.54% | 0.45% | -0.84% | -0.01% | 0.79% | 1.31% | 0.42% | 42.29% | 1.03% | -1.44% | 0.57% | 0.00% | 0.91% | 1.11% | 0.68% | 1.06% | 0.30% |
Xencor SG&A Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 7 | 6 | 5 | 5 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $15.27M | $12.49M | $11.46M | $13.95M | $12.75M | $12.37M | $11.09M | $11.27M | $11.38M | $10.37M | $8.86M | $8.23M | $7.60M | $7.64M | $7.23M | $7.22M | $6.75M | $6.27M |
Avg Forecast | $4.42M | $4.42M | $4.42M | $4.42M | $4.07M | $3.78M | $3.43M | $3.16M | $5.26M | $3.14M | $4.30M | $4.96M | $16.70M | $6.45M | $5.65M | $6.18M | $4.32M | $4.53M | $7.32M | $5.62M | $16.41M | $4.46M | $3.98M | $14.36M | $6.56M | $7.74M | $2.52M | $10.60M | $3.08M | $1.45M |
High Forecast | $4.42M | $4.42M | $4.42M | $4.42M | $4.07M | $3.78M | $3.43M | $3.16M | $5.26M | $6.89M | $4.42M | $4.96M | $26.10M | $6.45M | $5.65M | $6.18M | $4.32M | $4.53M | $7.32M | $5.62M | $16.41M | $4.46M | $3.98M | $17.24M | $6.56M | $7.74M | $2.52M | $12.72M | $3.08M | $1.45M |
Low Forecast | $4.42M | $4.42M | $4.42M | $4.42M | $4.07M | $3.78M | $3.43M | $3.16M | $5.26M | $296.04K | $4.18M | $4.96M | $2.37M | $6.45M | $5.65M | $6.18M | $4.32M | $4.53M | $7.32M | $5.62M | $16.41M | $4.46M | $3.98M | $11.49M | $6.56M | $7.74M | $2.52M | $8.48M | $3.08M | $1.45M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 1.94% | 2.03% | 2.26% | 2.95% | 2.73% | 1.52% | 2.00% | 0.69% | 2.33% | 2.23% | 0.57% | 1.16% | 0.99% | 2.87% | 0.68% | 2.19% | 4.33% |
Xencor EPS Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 7 | 6 | 5 | 5 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.31 | $-0.40 | $-0.37 | $-1.00 | $-0.20 | $-0.55 | $-0.67 | $0.40 | $1.25 | $-0.69 | $0.90 | $-0.04 | $-0.00 | $-0.22 | $-0.61 | $-0.14 | $-0.47 | $-0.18 |
Avg Forecast | $-0.89 | $-0.89 | $-0.90 | $-0.90 | $-1.00 | $-0.96 | $-0.97 | $-0.96 | $-0.79 | $-0.98 | $-0.83 | $-0.83 | $-0.11 | $-0.73 | $-0.80 | $-0.66 | $-0.79 | $-0.68 | $-0.49 | $-0.55 | $0.03 | $-0.63 | $-0.59 | $-0.67 | $-0.38 | $-0.22 | $-0.51 | $-0.38 | $-0.41 | $-0.55 |
High Forecast | $-0.89 | $-0.89 | $-0.90 | $-0.90 | $-1.00 | $-0.96 | $-0.97 | $-0.96 | $-0.79 | $-0.85 | $-0.83 | $-0.83 | $0.40 | $-0.73 | $-0.80 | $-0.66 | $-0.79 | $-0.68 | $-0.49 | $-0.55 | $0.03 | $-0.63 | $-0.59 | $-0.67 | $-0.38 | $-0.22 | $-0.51 | $-0.38 | $-0.41 | $-0.55 |
Low Forecast | $-0.89 | $-0.89 | $-0.90 | $-0.90 | $-1.00 | $-0.96 | $-0.97 | $-0.96 | $-0.79 | $-1.08 | $-0.83 | $-0.83 | $-0.56 | $-0.73 | $-0.80 | $-0.66 | $-0.79 | $-0.68 | $-0.49 | $-0.55 | $0.03 | $-0.63 | $-0.59 | $-0.67 | $-0.38 | $-0.22 | $-0.51 | $-0.38 | $-0.41 | $-0.55 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.92% | 0.55% | 0.46% | 1.51% | 0.25% | 0.81% | 1.36% | -0.73% | 44.63% | 1.09% | -1.53% | 0.06% | 0.00% | 0.98% | 1.19% | 0.37% | 1.14% | 0.33% |
Xencor Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
STRO | Sutro Biopharma | $3.69 | $11.14 | 201.90% | Buy |
FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
ANAB | AnaptysBio | $19.94 | $52.33 | 162.44% | Buy |
ERAS | Erasca | $2.87 | $7.00 | 143.90% | Buy |
MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
REPL | Replimune Group | $12.02 | $24.20 | 101.33% | Buy |
XNCR | Xencor | $21.52 | $42.60 | 97.96% | Buy |
SNDX | Syndax Pharmaceuticals | $18.94 | $36.11 | 90.65% | Buy |
KROS | Keros Therapeutics | $59.95 | $102.00 | 70.14% | Buy |
VRDN | Viridian Therapeutics | $22.84 | $37.83 | 65.63% | Buy |
IDYA | IDEAYA Biosciences | $30.00 | $48.36 | 61.20% | Buy |
MGTX | MeiraGTx | $5.96 | $9.00 | 51.01% | Buy |
MRUS | Merus | $51.23 | $77.13 | 50.56% | Buy |
KURA | Kura Oncology | $17.81 | $26.00 | 45.99% | Buy |
EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
NUVL | Nuvalent | $89.53 | $107.83 | 20.44% | Buy |
PCVX | Vaxcyte | $106.49 | $124.14 | 16.57% | Buy |
PTGX | Protagonist Therapeutics | $46.76 | $50.00 | 6.93% | Buy |
ACLX | Arcellx | $86.44 | $71.57 | -17.20% | Buy |
CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
XNCR Forecast FAQ
Is Xencor a good buy?
Yes, according to 6 Wall Street analysts, Xencor (XNCR) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of XNCR's total ratings.
What is XNCR's price target?
Xencor (XNCR) average price target is $42.6 with a range of $31 to $58, implying a 97.96% from its last price of $21.52. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Xencor stock go up soon?
According to Wall Street analysts' prediction for XNCR stock, the company can go up by 97.96% (from the last price of $21.52 to the average price target of $42.6), up by 169.52% based on the highest stock price target, and up by 44.05% based on the lowest stock price target.
Can Xencor stock reach $30?
XNCR's average twelve months analyst stock price target of $42.6 supports the claim that Xencor can reach $30 in the near future.
What are Xencor's analysts' financial forecasts?
Xencor's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $67.11M (high $67.11M, low $67.11M), average EBITDA is $-21.946M (high $-21.946M, low $-21.946M), average net income is $-240M (high $-240M, low $-240M), average SG&A $14.44M (high $14.44M, low $14.44M), and average EPS is $-3.884 (high $-3.884, low $-3.884). XNCR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $82.28M (high $82.28M, low $82.28M), average EBITDA is $-26.906M (high $-26.906M, low $-26.906M), average net income is $-221M (high $-221M, low $-221M), average SG&A $17.7M (high $17.7M, low $17.7M), and average EPS is $-3.58 (high $-3.58, low $-3.58).
Did the XNCR's actual financial results beat the analysts' financial forecasts?
Based on Xencor's last annual report (Dec 2023), the company's revenue was $168.34M, beating the average analysts forecast of $162.62M by 3.52%. Apple's EBITDA was $-138M, beating the average prediction of $-53.176M by 160.41%. The company's net income was $-126M, beating the average estimation of $-29.317M by 330.07%. Apple's SG&A was $53.38M, beating the average forecast of $34.98M by 52.61%. Lastly, the company's EPS was $-2.08, missing the average prediction of $-2.293 by -9.27%. In terms of the last quarterly report (Dec 2023), Xencor's revenue was $44.69M, missing the average analysts' forecast of $77.63M by -42.44%. The company's EBITDA was $-33.466M, beating the average prediction of $-25.386M by 31.83%. Xencor's net income was $-19.1M, beating the average estimation of $-6.54M by 192.07%. The company's SG&A was $15.27M, missing the average forecast of $16.7M by -8.54%. Lastly, the company's EPS was $-0.31, beating the average prediction of $-0.106 by 192.37%